Abstract:Background: Bladder cancer (BLCA) presents as a heterogeneous epithelial malignancy. Progress in the early detection and effective treatment of BLCA relies heavily on the identification of novel biomarkers. Therefore, the primary goal of this study is to pinpoint potential biomarkers for BLCA through the fusion of single-cell RNA sequencing and RNA sequencing assessments. Furthermore, the aim is to establish practical clinical prognostic models that can facilitate accurate categorization and individualized therapy for patients. Methods: In this research, training sets were acquired from the TCGA database, whereas validation sets (GSE32894) and single-cell datasets (GSE135337) were extracted from the GEO database. Single-cell analysis was utilized to obtain characteristic subpopulations along with their associated marker genes. Subsequently, a novel BLCA subtype was identified within TCGA-BLCA. Furthermore, an artificial neural network prognostic model was constructed within the TCGA-BLCA cohort and subsequently verified utilizing a validation set. Two machine learning algorithms were employed to screen hub genes. QRT-qPCR was performed to detect the gene expression levels utilized in the construction of prognostic models across various cell lines. Additionally, the cMAP database and molecular docking were utilized for searching small molecule drugs. Results: The results of single-cell analysis revealed the presence of epithelial cells in multiple subpopulations, with 1579 marker genes selected for subsequent investigations. Subsequently, four epithelial cell subtypes were identified within the TCGA-BLCA cohort. Notably, cluster A exhibited a significant survival advantage. Concurrently, an artificial neural network prognostic model comprising 17 feature genes was constructed, accurately stratifying patient risk. Patients categorized in the low-risk group demonstrated a considerable survival advantage. The ROC analysis suggested that the model has strong prognostic ability. Furthermore, the findings of the validation group align consistently with those from the training group. Two types of machine learning algorithms screened NFIC as hub genes. Forskolin, a small molecule drug that binds to NFIC, was identified by employing a cMAP database and molecular docking. Conclusion: The analysis results supplement the research on the role of epithelial cells in BLCA. An artificial neural network prognostic model containing 17 characteristic genes demonstrates the capability to accurately stratify patient risk, thereby potentially improving clinical decision-making and optimizing personalized therapeutic approaches.

Classification and diagnostic prediction of ovarian cancers using protein profiling of serum and artificial neural networks

Diagnostic Application of Serum Protein Pattern and Artificial Neural Network Software in Breast Cancer

The study on the identification of primary lesion unknown cancer with artificial neural network and serum tumor markers

Screening Ovarian Cancers with Raman Spectroscopy of Blood Plasma Coupled with Machine Learning Data Processing.

A Novel Classifier Based on Urinary Proteomics for Distinguishing Between Benign and Malignant Ovarian Tumors

An Integrated Approach Utilizing Proteomics and Bioinformatics to Detect Ovarian Cancer

Artificial intelligence-based preoperative prediction system for diagnosis and prognosis in epithelial ovarian cancer: A multicenter study

Machine Learning-Based LIBS Spectrum Analysis of Human Blood Plasma Allows Ovarian Cancer Diagnosis.

Automated early ovarian cancer detection system based on bioinformatics

Artificial Neural Networks Analysis Of Surface-Enhanced Laser Desorption/Ionization Mass Spectra Of Serum Protein Pattern Distinguishes Colorectal Cancer From Healthy Population

Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers

The stage for the nephroblastoma: Specific serum protein biomarkers or CT scan

Identification of epithelial-related artificial neural network prognostic models for the prediction of bladder cancer prognosis through comprehensive analysis of single-cell and bulk RNA sequencing

SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.

Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer

Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses

Construction of a Diagnostic Model for Distinguishing Benign or Malignant Bone Cancer by Mining miRNA Expression Data

Machine-learning diagnostic models for ovarian tumors

Ultrasound image analysis using deep neural networks for discriminating between benign and malignant ovarian tumors: comparison with expert subjective assessment

Preliminary Study of Serum Proteome Biomarkers of Hypopharyngeal Squamous Cell Carcinoma

Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population and brain benign tumo